Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.



Total Raised


Date of IPO


About Sansure Biotech

Sansure Biotech (688289.SH) focuses on molecular diagnosis and genetic testing techniques. The company provides innovative molecular diagnosis and genetic testing kits and tools to diagnostic labs and researchers.

Sansure Biotech Headquarters Location

No.680, Lusong Road, Hi-Tech Development Zone Yuelu District, Hunan Province

Changsha, Hunan, 410205,


+86 0731-88883176

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Sansure Biotech

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sansure Biotech is included in 5 Expert Collections, including Digital Health.


Digital Health

13,583 items


Medical Devices

8,490 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health Monitoring & Diagnostics

2,421 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data


Health IT

7,901 items

Sansure Biotech Patents

Sansure Biotech has filed 3 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Animal virology
  • Biotechnology
patents chart

Application Date

Grant Date


Related Topics




Molecular biology, Drug delivery devices, Biotechnology, Dosage forms, Molecular biology techniques


Application Date


Grant Date



Related Topics

Molecular biology, Drug delivery devices, Biotechnology, Dosage forms, Molecular biology techniques



Latest Sansure Biotech News

QuantuMDx Enters into Cooperation Agreement with Sansure Biotech

Sep 6, 2022

Biotech The agreement sets a roadmap for the commercialisation of Q-POC™ and its assays in China The two companies will collaborate to accelerate the development of new assays on the Q-POC™ platform Offers potential for component sourcing and manufacturing optimisation NEWCASTLE UPON TYNE, UK, 6 September 2022. QuantuMDx Group Limited (“QuantuMDx”), today announces it has entered into a cooperation agreement with Sansure Biotech Inc. (“Sansure”), an in-vitro diagnostic solution provider based in Changsha, Hunan province, China, to accelerate the regional commercialisation of Q-POC™ and its assays, in China. Under the terms of the agreement, QuantuMDx and Sansure will enter a global R&D, manufacturing and commercial partnership aimed to bring a comprehensive array of innovative, high-performance molecular diagnostic assays to the Q-POC™ platform. QuantuMDx will grant Sansure exclusive rights to Q-POC™ in China, for which QuantuMDx will receive licensing and royalty payments. QuantuMDx will also have the exclusive rights to sell Sansure-translated assays outside China. This agreement follows a £15 million equity investment in November 2021 , from Vita Spring IVD Fund, L.P., a Hong Kong-based venture capital firm focused on early and growth-stage medical companies with disruptive technologies and global market potential. Financial terms of the agreement were not disclosed. Jonathan O’Halloran, Chief Executive, QuantuMDx, said: “Sansure is an excellent partner for QuantuMDx in China as we look to increase our global presence. This cooperation agreement will now enable both companies to explore and leverage reagent, components of the Q-POC™ instrument and cassette assays for cost down opportunities and scalability in China, with an expectation to reduce our cost of goods. Coupled with Sansure’s expert knowledge of commercialising molecular diagnostics in the region, I believe we are well placed to build a strong presence in China and other territories in this important market. "This agreement comes at a pivotal time for QuantuMDx following the recent launch of our new respiratory panel Q-POC™ SARS-CoV-2, Flu A/B & RSV Assay. As we all know, the attractiveness of Point of Need devices increases significantly with a wide assay menu. This agreement will enable us to rapidly expand our menu as well as help to drive our costs down.” Dr. Jia Liu, VP of R&D at Sansure, said: “The ability to use QuantuMDx’s Q-POC™ platform across multiple indications, demonstrated by the recent launch of its respiratory panel, is very exciting. There is a serious unmet need for accurate Point of Need testing, and we are looking forward to working with the innovative team at QuantuMDx, with the ultimate goal of bringing precision healthcare solutions to Chinese patients with this highly innovative diagnostic platform and a tailor-made portfolio of assays.” ### About QuantuMDx QuantuMDx is a progressive MedTech company passionate about empowering the world to control disease and reduce suffering. QuantuMDx solves real-world diagnostic problems by creating multiplex molecular solutions for the Point of Need. QuantuMDx has global operations and strategic partnerships – keeping it at the forefront of molecular diagnostics. Q-POC™ is a rapid, simple to use, portable, sample to answer multiplex PCR device. It has been designed for use in a range of real-world healthcare settings. Q-POC™ and its tests, Q-POC SARS-CoV-2 Assay, a multiplex COVID-19 detection assay and Q-POC SARS-CoV-2, Flu A/B & RSV Assay, a multiplex, multi-disease target assay, are CE marked under the In Vitro Diagnostics Directive (98/79/EC) enabling use within Europe. Q-POC SARS-CoV-2 Assay is CTDA approved allowing use in UK. Q-POC SARS-CoV-2, Flu A/B & RSV Assay is under CTDA review. On 26th May the Q-POC instrument was CE marked under IVDR enabling continued use in Europe following the change in regulation. QuantuMDx plans to launch a range of syndromic multiplex testing assays over the coming months and years. For more information about QuantuMDx and Q-POC™, its rapid PCR point of care system, go to: . About Sansure: Sansure is an in-vitro diagnostic solution provider founded in Changsha, Hunan province, China in 2008, with over 2,000 employees and a broad product portfolio. It is engaged in research and development, production and sales of diagnostic reagents and instruments. Sansure listed on the Shanghai Stock Exchange’s STAR Market on 28 August 2020 raising RMB2.0 billion (c.US$300 million), and as of 27 July 2022 had a market capitalisation of approximately RMB17.5 billion (c.US$2.6 billion). It was also one of the first molecular diagnostics companies to have its SARS-CoV-2 test kits approved in China, which are now sold to over 160 countries. Sansure’s founder and Chairman, Dr Li Zhong Dai, is a scientific advisor to Vita Spring. For more information about Sansure, go to: For media enquiries and interview requests: Emma Long, Marketing Communications Manager, QuantuMDx, M: +44 (0) 7495 341 930 T: +44 (0) 870 803 1234  E: Chris Gardner, Matthew Neal and Lindsey Neville, Consilium Strategic Communications, +44 (0)20 3709 5700 / For investor enquiries: David Wilson, Nigel Barnes and Robin Stürken, WG Partners (Financial Adviser to QuantuMDx), +44 (0)20 3705 9330 /

Sansure Biotech Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Sansure Biotech Rank

  • Where is Sansure Biotech's headquarters?

    Sansure Biotech's headquarters is located at No.680, Lusong Road, Hi-Tech Development Zone, Changsha.

  • What is Sansure Biotech's latest funding round?

    Sansure Biotech's latest funding round is IPO.

  • How much did Sansure Biotech raise?

    Sansure Biotech raised a total of $77M.

  • Who are the investors of Sansure Biotech?

    Investors of Sansure Biotech include Green Pine Capital Partners, Jiawo Capital, Shenzhen GTJA Investment Group, Junhe Capital, Zhang Chenbang and 5 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.